Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moclobemide for depression: an Australian psychiatric practice study

J W Tiller1, G F Johnson, G D Burrows

  • 1Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia.

Journal of Clinical Psychopharmacology
|August 1, 1995
PubMed
Summary

Moclobemide effectively treated major depression in 712 patients, with 65% showing moderate improvement. This real-world study found moclobemide well-tolerated, with most adverse events mild and short-lived.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relaxation theory and practice.

The Australian journal of physiotherapy·2014
Same author

Relaxation, the physiotherapist and the psychiatric patient.

The Australian journal of physiotherapy·2014
Same author

A multidimensional approach to the assessment of pain.

The Australian journal of physiotherapy·2014
Same author

Elevated plasma paroxetine concentrations in a patient treated with a combination of paroxetine and pindolol.

International journal of psychiatry in clinical practice·2014
Same author

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

International clinical psychopharmacology·2004
Same author

The identification and treatment of depression by general practitioners.

The Australian and New Zealand journal of psychiatry·2002

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Major depression is a prevalent mental health condition requiring effective treatment.
  • Real-world studies are crucial to understand antidepressant efficacy and tolerability beyond controlled trials.
  • Moclobemide, a reversible inhibitor of monoamine oxidase A, offers a treatment option for depression.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of moclobemide in a large, unselected patient population with major depression.
  • To assess treatment outcomes in routine psychiatric practice.

Main Methods:

  • A total of 712 patients diagnosed with major depression received moclobemide treatment.
  • Patients were treated in ordinary psychiatric practices, including both outpatients and inpatients.
  • Data collected included patient demographics, treatment history, adverse events, concomitant medications, and physician global impression.

Related Experiment Videos

Main Results:

  • 65% of patients showed moderate improvement or better after 8 weeks of moclobemide treatment.
  • 52% of patients reported no adverse events; common events included insomnia, nausea, and headache, mostly mild and transient.
  • Concomitant medication use in 73% of patients did not result in adverse interactions.

Conclusions:

  • Moclobemide demonstrates significant efficacy and good tolerability in the routine treatment of major depression.
  • The drug is effective in a broad patient population, including those with prior treatment failures or comorbidities.
  • Real-world data support moclobemide as a valuable therapeutic option for major depressive disorder.